Articles

Original Article

Treatment of Primary Tumor in Oligometastatic Prostate Cancer: An Observational Study of the Turkish Urooncology Association Prostate Diseases Working Group

Murat Yavuz Koparal
Tevfik Sinan Sözen
Güven Aslan
Sümer Baltacı
Oğuzcan Erbatu
Levent Türkeri
on Behalf of the Turkish Urooncology Association

Bull Urooncol 2023; 22: 62-67 DOI: 10.4274/uob.galenos.2023.2023.1.4

Review

A New Era in Metastatic Prostate Cancer: “The Combination of Chemotherapy and Hormonal Treatment as Initial Treatment”

İlker Tinay
Levent Türkeri

Bull Urooncol 2016; 15: 65-68 DOI: 10.4274/uob.434

Hormonal treatment of metastatic prostate cancer: Today and future

Hasan Soydan
Kadir Baykal

Bull Urooncol 2011; 10: 76-81

Are there any treatment option for metastatic prostate cancer refractory to docetaksel?

Yaşar Bedük

Bull Urooncol 2011; 10: 85-89

Intermittent Versus Continuous Androgen Deprivation in Patients with Metastatic Prostate Cancer: Review

Mehmet Yıldızhan
Mehmet Dündar
Mehmet Şirin Ertek

Bull Urooncol 2015; 14: 97-101 DOI: 10.4274/uob.315

Update in the management of skeletal related events for metastatic prostate cancer: Denosumab, Alfaradin

Serdar Çelik
Uğur Mungan

Bull Urooncol 2012; 11: 164-167

Review

Current Status of Oligometastatic Prostate Cancer: Risk Factors and Treatment Approaches

Fuat Kızılay

Bull Urooncol 2018; 17: 105-112 DOI: 10.4274/uob.1088

Case Report

Neutropenic Fever, Skin and Eye Toxicities Develops During Docetaxel Treatment in Metastatic Prostate Cancer: A Case Report

Erdem Şen
İrem Öner
Özlem Ata

Bull Urooncol 2017; 16: 133-136 DOI: 10.4274/uob.908

Article - Comment

Prediction of Response to Androgen Deprivation Therapy and Castration Resistance in Primary Metastatic Prostate Cancer

Ali F. Şahin

Bull Urooncol 2012; 11: 178-180

About Journal

Forms

Useful Links

Latest Update: 04.04.2024